Cetera Investment Advisers Has $20.46 Million Holdings in IQVIA Holdings Inc. $IQV

Cetera Investment Advisers grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 119,946 shares of the medical research company’s stock after purchasing an additional 7,517 shares during the quarter. Cetera Investment Advisers’ holdings in IQVIA were worth $20,456,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC boosted its position in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of IQVIA in the second quarter valued at about $514,000. First Trust Advisors LP increased its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC increased its position in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock opened at $212.76 on Tuesday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a fifty day moving average of $189.02 and a 200-day moving average of $186.85. The stock has a market capitalization of $35.51 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IQV. Mizuho increased their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Robert W. Baird raised their price objective on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. HSBC reaffirmed a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a report on Thursday, July 9th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.